Video

Analyzing GEMINI 1 clinical trial results of presbyopia eye drop

Author(s):

Sheryl Stevenson,Alex Delaney-Gesing
Conferences|ASCRS

George O. Waring IV, MD, FACS, discusses the latest results from the GEMINI 1 clinical trial of AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia.

George O. Waring IV, MD, FACS, of the Waring Vision Institute (Mount Pleasant, SC), discusses the latest results from the GEMINI 1 clinical trial (by Allergan, an Abbvie company) of AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia.

See more ASCRS coverage

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Related Content
Q&A: Michael Lai, MD, PhD, on the impact of underfunding the Good Days program
August 8th 2025

Q&A: Michael Lai, MD, PhD, on the impact of underfunding the Good Days program

3 Things You Should Know About the GA Pipeline
August 8th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Q&A: The potential impact of vitamin D on retinal surgery
August 8th 2025

Q&A: The potential impact of vitamin D on retinal surgery

Patient-Centered Treatment Strategies in the Management of nAMD and DME
August 8th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Q&A: A VERONA trial update with Yasha S. Modi, MD
August 8th 2025

Q&A: A VERONA trial update with Yasha S. Modi, MD

(Image credit: Wills Eye Hospital) Wills Eye Hospital names Julia A. Haller, MD, as new chief executive officer
August 8th 2025

Wills Eye Hospital names Julia A. Haller, MD, as new chief executive officer

© 2025 MJH Life Sciences

All rights reserved.